Navigation Links
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
Date:2/25/2010

BUFFALO, N.Y., Feb. 25 /PRNewswire/ -- Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer.  

Dr. Kwan has had a successful career in the pharmaceutical industry and brings to Kinex over twenty years of experience in clinical operations.  Most recently he served dual roles at Schering Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS.

In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific.  

As Vice President of Global Clinical Development, CNS, Dr. Kwan was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration.  He also designed and executed multiple phase 2 development programs.

Earlier at Schering Plough, Dr. Kwan held various clinical operation positions with increasing responsibility.  He held similar positions at Chiron Corporation and at Smith Kline Beecham.

Dr. Kwan obtained an MD degree in Hong Kong and did subsequent training in England.  He has served as Chair of the Data Monitoring and Safety Board for the National Institute on Deafness and other Communication Disorders for trials on Celecoxib as an adjunct to surgery for Recurrent Respiratory Papillomatosis. Currently, he is a member and Chair, of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse (NIDA) of the National Institute of Health.  He is also a member of several advisory panels and grant review panels for NIDA.

"Kinex Pharmaceuticals is extremely pleased to announce that Dr. Rudolf Kwan is joining us as Chief Medical Officer.  He brings with him a distinguished career of achievements in clinical operations in the pharmaceutical industry," said Dr. Allen Barnett, CEO of Kinex.  

At Kinex Pharmaceuticals, Dr. Kwan will be responsible for the design and execution of the Company's clinical development programs.  In 2010, Kinex will be launching several Phase 2 studies in oncology for KX2-391 as well as a Phase 1 trial in brain cancer for KX2-361.  "Dr. Kwan's appointment comes at a critical point in our Company's development as we transition from a drug discovery company to a development company with multiple compounds in clinical development," said Dr. Barnett.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit www.kinexpharma.com.

SOURCE Kinex Pharmaceuticals

Back to top

RELATED LINKS
http://www.kinexpharma.com

'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
3. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
4. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
5. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
6. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Innovative University of Cincinnati Program Trains Next Generation of Pharmaceutical Professionals
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
10. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
11. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ANGELES , Feb. 5, 2016  Redwood Scientific ... a new product designed to help women balance their ... strip delivery technology. Jason Cardiff , ... will be able to help the millions of women ... from the effects of imbalanced hormones. Our research and ...
(Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association ... restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 ... ALS and related diseases that severely limit strength and mobility. , Now ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
Breaking Medicine News(10 mins):